T. Rowe Price Associates
FLXN

T. Rowe Price Associates’s Flexion Therapeutics, Inc. FLXN Stock Holding History

T. Rowe Price Associates’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-34,451
Closed -$210K – 3102
2021
Q3 		$210K Buy
34,451
+15,393
+81% +$95.9K ﹤0.01% 2707
2021
Q2 		$157K Buy
19,058
+507
+3% +$4.31K ﹤0.01% 2776
2021
Q1 		$166K Buy
+18,551
New +$213K ﹤0.01% 2730
2020
Q4 		– Sell
-16,100
Closed -$168K – 2747
2020
Q3 		$168K Buy
16,100
+687
+4% +$8.42K ﹤0.01% 2458
2020
Q2 		$203K Buy
15,413
+211
+1% +$2.19K ﹤0.01% 2352
2020
Q1 		$120K Buy
+15,202
New +$229K ﹤0.01% 2395
2018
Q4 		– Sell
-15,087
Closed -$282K – 2606
2018
Q3 		$282K Buy
15,087
+3,703
+33% +$85.1K ﹤0.01% 2375
2018
Q2 		$294K Buy
11,384
+36
+0.3% +$934 ﹤0.01% 2353
2018
Q1 		$254K Buy
11,348
+74
+0.7% +$1.81K ﹤0.01% 2348
2017
Q4 		$282K Buy
+11,274
New +$276K ﹤0.01% 2303

T. Rowe Price Associates's FLXN Position: Q4 2021 in Review

T. Rowe Price Associates sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2021, closing a stake of 34,451 shares — an estimated $210K sold.

T. Rowe Price Associates first reported a position in FLXN in Q4 2017 and held it in 10 quarters. The position peaked at $294K in Q2 2018. 1 fund tracked by Wall St. Rank holds FLXN as of Q4 2021.

  • T. Rowe Price Associates reported no remaining Flexion Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 34,451 Flexion Therapeutics, Inc. shares in Q4 2021, an estimated $210K.
  • T. Rowe Price Associates first reported a position in Flexion Therapeutics, Inc. in Q4 2017 and held it in 10 quarters.
  • T. Rowe Price Associates's Flexion Therapeutics, Inc. position peaked at $294K in Q2 2018.
  • 1 fund tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2021.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.